Outlook Therapeutics (OTLK) News Today $1.42 -0.08 (-5.33%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Outlook Therapeutics files to sell 7.07M shares of common stock for holdersMarch 1 at 10:09 AM | markets.businessinsider.comOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationFebruary 28 at 8:05 AM | globenewswire.comAscendiant Capital Markets Lowers Outlook Therapeutics (NASDAQ:OTLK) Price Target to $24.00February 26, 2025 | americanbankingnews.comHC Wainwright Has Negative Forecast for OTLK Q2 EarningsFebruary 22, 2025 | americanbankingnews.comResearch Analysts Set Expectations for OTLK Q2 EarningsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Outlook Therapeutics in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per shaFebruary 21, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OTLK Q1 Earnings?February 21, 2025 | americanbankingnews.comQ1 Earnings Estimate for OTLK Issued By HC WainwrightOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Outlook Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao expects that the company will post earningFebruary 20, 2025 | marketbeat.comOutlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comOutlook Therapeutics price target lowered to $10 from $12 at GuggenheimFebruary 19, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday.February 19, 2025 | marketbeat.comOutlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan CapitalChardan Capital reaffirmed a "neutral" rating and issued a $3.00 price objective on shares of Outlook Therapeutics in a research note on Tuesday.February 19, 2025 | marketbeat.comOutlook Therapeutics price target lowered to $3 from $30 at H.C. WainwrightFebruary 18, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Releases Earnings Results, Misses Estimates By $0.04 EPSOutlook Therapeutics (NASDAQ:OTLK - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04).February 15, 2025 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPSOutlook Therapeutics (NASDAQ:OTLK - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04).February 15, 2025 | marketbeat.comOutlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last yearFebruary 14, 2025 | markets.businessinsider.comOutlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate UpdateFebruary 14, 2025 | globenewswire.comOutlook Therapeutics (OTLK) to Release Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Wednesday, February 12, Financial Modeling Prep reports.February 10, 2025 | marketbeat.comAnalysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $27.40Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the companFebruary 10, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buyFebruary 7, 2025 | marketbeat.comOutlook Therapeutics (OTLK) to Release Quarterly Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Wednesday, February 12, Financial Modeling Prep reports.February 5, 2025 | marketbeat.comOutlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentFebruary 4, 2025 | globenewswire.comOutlook Therapeutics names new chairman amid product launchJanuary 31, 2025 | msn.comOutlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of DirectorsJanuary 31, 2025 | globenewswire.comOutlook Therapeutics announces presentation of data from NORSE EIGHTJanuary 23, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMDJanuary 23, 2025 | globenewswire.comOutlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarJanuary 22, 2025 | globenewswire.comChardan Capital Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)January 21, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday.January 18, 2025 | marketbeat.comNew Hacking Disaster Warning For Gmail, Outlook, Apple Mail UsersJanuary 17, 2025 | forbes.comCritical Microsoft Outlook Vulnerability Rated 9.8/10 Confirmed—Update NowJanuary 17, 2025 | forbes.comPositive Outlook for Outlook Therapeutics Driven by Promising ONS-5010 Data and Strategic Market PositioningJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from GuggenheimGuggenheim restated a "buy" rating and set a $12.00 target price on shares of Outlook Therapeutics in a research note on Friday.January 17, 2025 | marketbeat.comOutlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Friday.January 17, 2025 | marketbeat.comShort Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7%Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,890,000 shares, a drop of 17.7% from the December 15th total of 3,510,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 18.0% of the shares of the stock are sold short.January 17, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical TrialJanuary 17, 2025 | finanznachrichten.deOutlook Therapeutics’ ONS-5010 shown to be non-inferior to Lucentis in wet AMDJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics enters into agreement for warrant inducement transactionJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical TrialJanuary 16, 2025 | globenewswire.comAnalysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $32.73Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assignedJanuary 16, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendaJanuary 13, 2025 | marketbeat.comOutlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentJanuary 8, 2025 | globenewswire.comOutlook Therapeutics provides ONS-5010/LYTENAVA updateDecember 28, 2024 | finance.yahoo.comOutlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration TreatmentDecember 27, 2024 | marketwatch.comOutlook Therapeutics reports FY24 EPS ($4.06) vs. ($4.72) last yearDecember 27, 2024 | markets.businessinsider.comOutlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdateDecember 27, 2024 | globenewswire.comATX Ahead: 2025 Economic Outlook event coming in JanuaryDecember 18, 2024 | bizjournals.comOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial LaunchDecember 13, 2024 | marketwatch.comOutlook Therapeutics® Streamlines OperationsDecember 13, 2024 | globenewswire.comBTIG Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)December 11, 2024 | markets.businessinsider.comOutlook Therapeutics announces NICE recommendation of LYTENAVADecember 4, 2024 | markets.businessinsider.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.190.70▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼44▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genfit News Today Cybin News Today Pliant Therapeutics News Today Ocugen News Today Compugen News Today Enanta Pharmaceuticals News Today Inhibikase Therapeutics News Today Inhibrx News Today CARGO Therapeutics News Today INmune Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBefore it hits CNBC: AI was just the warm-up act (see his next prediction)During a routine analysis of my proprietary data, something caught my eye. A small American tech company with ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts